Dec-21-20 Downgrade
Jefferies
Buy → Hold
$14
Apr-01-20 Downgrade
Oppenheimer
Outperform → Perform
Mar-04-20 Initiated
Barclays
Overweight
$33
Feb-25-20 Reiterated
H.C. Wainwright
Buy
$25 → $36
Jan-24-20 Downgrade
SVB Leerink
Outperform → Mkt Perform
Dec-06-19 Upgrade
Morgan Stanley
Equal-Weight → Overweight
May-30-19 Resumed
Citigroup
Buy
Jan-07-19 Upgrade
Leerink Partners
Mkt Perform → Outperform
Sep-07-18 Resumed
Morgan Stanley
Equal-Weight
Jul-03-18 Downgrade
Leerink Partners
Outperform → Mkt Perform
Jan-24-18 Resumed
Jefferies
Buy
$25
Jan-10-18 Initiated
Morgan Stanley
Overweight
$20
Nov-02-17 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$20 → $16
Sep-20-17 Initiated
Jefferies
Buy
$23
May-10-17 Resumed
RBC Capital Mkts
Outperform
$19 → $20
Apr-13-17 Initiated
Oppenheimer
Outperform
May-10-16 Reiterated
Mizuho
Buy
$20 → $18
Apr-05-16 Initiated
Citigroup
Buy
$17
Mar-14-16 Upgrade
H.C. Wainwright
Neutral → Buy
$25
Mar-10-16 Reiterated
Wedbush
Outperform
$33 → $22
Dec-18-20 02:43PM
Dec-06-20 11:30AM
Nov-29-20 12:30PM
Nov-16-20 05:16AM
Nov-13-20 12:56PM
Nov-11-20 04:05PM
06:15AM
Nov-10-20 05:50AM
Nov-09-20 10:16AM
Nov-08-20 09:24AM
Nov-06-20 07:31PM
07:53AM
07:45AM
06:30AM
06:05AM
06:00AM
Oct-30-20 06:30AM
Oct-28-20 12:33PM
Oct-07-20 03:29PM
06:30AM
Oct-02-20 09:21AM
Sep-08-20 06:30AM
Sep-03-20 11:31AM
Aug-18-20 01:05PM
Aug-05-20 11:29AM
Aug-04-20 05:00PM
07:45AM
07:18AM
06:30AM
Jul-28-20 06:30AM
Jul-16-20 06:31PM
Jun-28-20 09:31AM
Jun-20-20 07:57AM
Jun-19-20 10:19AM
10:02AM
09:41AM
Jun-18-20 01:31PM
08:34AM
Jun-17-20 01:56PM
Jun-16-20 07:09AM
Jun-03-20 11:30AM
May-26-20 12:55PM Thomson Reuters StreetEvents
May-14-20 09:22AM
May-13-20 05:12PM
May-07-20 10:51AM
May-05-20 09:11AM
May-04-20 07:00PM
07:45AM
07:04AM
06:30AM
Apr-27-20 12:32PM
06:30AM
Apr-26-20 10:02AM
Apr-19-20 07:02AM
Apr-08-20 06:56PM
Mar-25-20 11:30AM
Mar-20-20 06:30AM
Mar-06-20 03:41AM Thomson Reuters StreetEvents
Feb-26-20 06:39AM
Feb-25-20 12:09PM
09:38AM
09:28AM
05:17AM American City Business Journals
Feb-24-20 07:45AM
06:30AM
06:30AM
Feb-23-20 06:38PM
Feb-20-20 08:42AM
Feb-19-20 09:21AM
Feb-18-20 06:30AM
Feb-14-20 08:23AM
06:30AM
Feb-12-20 06:55AM
Feb-06-20 05:50PM
Feb-05-20 11:52AM
Jan-31-20 05:50PM
Jan-29-20 09:59AM
Jan-24-20 12:00PM
10:44AM
09:57AM
05:52AM
Jan-23-20 06:07PM American City Business Journals
05:16PM
09:34AM
09:04AM
Jan-22-20 11:30AM
10:00AM
08:57AM
Jan-21-20 09:26AM
Jan-20-20 02:04PM
09:32AM
Jan-17-20 08:45AM
Jan-09-20 04:47PM
Jan-08-20 12:00PM
Jan-07-20 10:26AM
09:19AM
Jan-06-20 06:30AM
Dec-30-19 09:24AM
Dec-26-19 10:38AM
Dec-24-19 08:15AM
Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma epithelioid sarcoma in the United States. It also develops Tazemetostat in combination with rituximab in patients with relapsed and refractory follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors and blood cancers; and PRMT1 inhibitor for solid tumors and DLBCL. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Agarwal Shefali Chief Medical Officer Dec 03 Sale 13.54 2,522 34,148 76,089 Dec 07 07:00 AM GOLDFISCHER CARL Director Nov 11 Buy 12.07 5,000 60,350 5,000 Nov 13 07:05 AM Beaulieu Joseph Corporate Controller Sep 02 Sale 12.88 543 6,994 5,958 Sep 03 09:30 PM MOTT DAVID M Director Jun 26 Buy 16.03 62,019 994,165 82,601 Jun 26 07:12 PM Beaulieu Joseph Corporate Controller Jun 26 Sale 16.15 317 5,120 4,838 Jun 30 09:04 AM Bazemore Robert B President & CEO Jun 26 Sale 16.15 4,773 77,084 250,098 Jun 30 09:01 AM Agarwal Shefali Chief Medical Officer Jun 26 Sale 16.15 1,805 29,151 78,611 Jun 30 08:56 AM TOMBESI PAOLO Chief Financial Officer Jun 26 Sale 16.15 1,805 29,151 21,942 Jun 30 08:57 AM Ros Matthew See Remarks Jun 26 Sale 16.15 2,728 44,057 57,507 Jun 30 08:54 AM Bazemore Robert B President & CEO Jun 18 Option Exercise 8.98 10,000 89,800 264,371 Jun 22 07:36 PM Ros Matthew See Remarks Jun 18 Option Exercise 9.47 112,003 1,060,669 120,449 Jun 22 07:31 PM Bazemore Robert B President & CEO Jun 18 Sale 22.00 20,000 440,000 244,371 Jun 22 07:36 PM Ros Matthew See Remarks Jun 18 Sale 21.24 112,003 2,378,444 51,798 Jun 22 07:31 PM Beaulieu Joseph Corporate Controller Mar 25 Sale 15.28 212 3,239 4,961 Mar 26 09:11 PM TOMBESI PAOLO Chief Financial Officer Mar 25 Sale 15.28 1,243 18,993 15,437 Mar 26 09:01 PM Ros Matthew See Remarks Mar 25 Sale 15.28 1,243 18,993 51,798 Mar 26 09:01 PM Agarwal Shefali Chief Medical Officer Mar 25 Sale 15.28 1,243 18,993 71,991 Mar 26 09:00 PM Bazemore Robert B President & CEO Mar 25 Sale 15.28 3,285 50,195 254,371 Mar 26 09:00 PM Allen Andrew R Director Mar 16 Option Exercise 9.33 12,500 116,625 12,500 Mar 18 04:30 PM Beaulieu Joseph Corporate Controller Mar 03 Sale 22.18 996 22,091 3,617 Mar 05 06:52 PM Bazemore Robert B President & CEO Jan 27 Sale 20.44 6,074 124,153 84,668 Jan 27 09:17 PM Agarwal Shefali Chief Medical Officer Jan 27 Sale 20.44 2,630 53,757 58,803 Jan 27 09:19 PM Agarwal Shefali Chief Medical Officer Jan 24 Sale 24.64 1,843 45,412 61,433 Jan 27 09:19 PM Bazemore Robert B President & CEO Jan 24 Sale 24.62 3,002 73,909 90,742 Jan 27 09:17 PM Ros Matthew See Remarks Jan 24 Sale 24.64 1,847 45,510 42,185 Jan 27 09:18 PM Beaulieu Joseph Corporate Controller Jan 24 Sale 24.63 330 8,128 1,042 Jan 27 09:16 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite